Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, has been...
BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation of...
BERG, a clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the underlying biology of disease, today...
BERG, the clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the biology of underlying disease, today...
BERG, ein auf klinischer Stufe aktives Biopharma-Unternehmen, das mithilfe von künstlicher Intelligenz (KI) und Multi-Omik neuartige biologische...
BERG, une société biopharmaceutique de stade clinique qui utilise l'intelligence artificielle (IA) et la multi-omique pour identifier de nouvelles...
- BERG presenta los primeros datos obtenidos por medio de su tecnología bayesiana con IA Interrogative Biology® para trazar la biología subyacente de ...
BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease...
BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation...
BERG, a biopharmaceutical company, that combines biology and technology to discover novel biology underlying disease, today announced four...
BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced four abstracts...
Berg Analytics, a division of BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases,...
BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings...
BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the...
BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today presented in a poster...
BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced that the U.S....
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts ...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the dosing of the first patient...
BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, Massachusetts General Hospital (MGH), and...
BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort with Sanofi Pasteur, the influenza...
BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in Progress Award ...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the completion of clinical...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced two poster presentations showing ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.